aDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA
bIAVI Neutralizing Antibody Center at TSRI, La Jolla, California, USA
cIntegrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA
dLaboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA
eVaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA
Citation Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT. 2015. Correction for Ingale et al., Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. J Virol 89:6526. doi:10.1128/JVI.00596-15.